Neipp M, Exner B G, Maru D, Haber M, Gammie J S, Pham S M, Ildstad S T
Institute for Cellular Therapeutics, University of Louisville, KY, USA.
Exp Hematol. 1999 May;27(5):860-7. doi: 10.1016/s0301-472x(99)00015-6.
Bone marrow chimerism may solve two major limitations in the transplantation of solid organs and cellular grafts: (1) the requirement for life-long immunosuppressive therapy, and (2) acute and chronic rejection. When untreated bone marrow is transplanted into major histocompatibility complex (MHC)-disparate rats, lethal graft-vs-host disease (GVHD) occurs in the majority of recipients. T-cell depletion using anti-CD3 and anti-CD5 monoclonal antibody (mAb) to avoid GVHD led to an increased occurrence of failure of engraftment. We previously identified a cellular population in mouse bone marrow that facilitates engraftment of highly purified hematopoietic stem cells (HSC) across complete MHC barriers. In light of the fact that facilitating cells have a CD8+/CD3+/TCR- phenotype and mostly coexpress CD5, we evaluated in this study whether T-cell depletion of rat bone marrow using anti-alphabetaTCR mAb would retain engraftment potential yet avoid GVHD. T-cell depletion of bone marrow was performed using anti-alphabetaTCR mAb and immunomagnetic beads. Recipients were conditioned with 1100 or 1000 cGy of total body irradiation and reconstituted with 100 x 10(6) T-cell depleted (TCD) MHC- and minor antigen-disparate bone marrow cells. Animals were monitored clinically and histologically for GVHD. Chimerism was assessed by flow cytometry. Immunomagnetic bead depletion resulted in a reduction of T cells from 1.92%+/-0.21% to 0.10%+/-0.04% of total bone marrow. T-cell depletion did not remove facilitating cells (CD8+/alphabetaTCR-/gammadeltaTCR-/NK3.2.3-) from bone marrow. Further, the engraftment potential of TCD bone marrow was not affected, as 100% of animals engrafted and high levels of donor chimerism were detectable. Animals reconstituted with TCD bone marrow showed no clinical evidence of GVHD and histology revealed none to minimal changes, whereas recipients transplanted with untreated bone marrow succumbed to severe lethal GVHD. T-cell depletion using antialphabetaTCR mAb and immunomagnetic beads selectively removes T cells from the bone marrow graft while sparing facilitating cells that are required for engraftment of allogeneic bone marrow across MHC barriers. Moreover, the cells required for engraftment of HSC do not produce GVHD.
(1)终身免疫抑制治疗的必要性,以及(2)急性和慢性排斥反应。当将未经处理的骨髓移植到主要组织相容性复合体(MHC)不相合的大鼠体内时,大多数受者会发生致死性移植物抗宿主病(GVHD)。使用抗CD3和抗CD5单克隆抗体(mAb)清除T细胞以避免GVHD会导致植入失败的发生率增加。我们之前在小鼠骨髓中鉴定出了一种细胞群体,它能促进高度纯化的造血干细胞(HSC)跨越完整的MHC屏障实现植入。鉴于促进细胞具有CD8 + / CD3 + / TCR - 表型且大多共表达CD5,我们在本研究中评估了使用抗αβTCR mAb对大鼠骨髓进行T细胞清除是否能保留植入潜力同时避免GVHD。使用抗αβTCR mAb和免疫磁珠对骨髓进行T细胞清除。受者接受1100或1000 cGy的全身照射预处理,并用100×10⁶个经T细胞清除(TCD)的MHC和次要抗原不相合的骨髓细胞进行重建。对动物进行临床和组织学监测以观察GVHD。通过流式细胞术评估嵌合现象。免疫磁珠清除导致T细胞在总骨髓中的比例从1.92%±0.21%降至0.10%±0.04%。T细胞清除并未从骨髓中去除促进细胞(CD8 + /αβTCR - /γδTCR - /NK3.2.3 - )。此外,TCD骨髓的植入潜力未受影响,因为100%的动物实现了植入且可检测到高水平的供体嵌合现象。用TCD骨髓重建的动物未表现出GVHD的临床证据,组织学检查显示无变化至轻微变化,而移植未经处理骨髓的受者则死于严重的致死性GVHD。使用抗αβTCR mAb和免疫磁珠进行T细胞清除可选择性地从骨髓移植物中去除T细胞,同时保留同种异体骨髓跨越MHC屏障植入所需的促进细胞。此外,HSC植入所需的细胞不会引发GVHD。